Stock Updates

How has Medivation, Inc.:(NASDAQ:MDVN) performed recently?

Medivation, Inc. (NASDAQ: MDVN) is a large market cap stock with a market cap of 13324.82. It is in the Biotechnology industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of 36.82 and EPS of -1.17. At a stock price of 80.33 (0.07%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 50.90%, more recently this last year it has grown by -11.10%. The next year growth is going to be about 70.98% and more long-term 37.68% after five years. EPS growth quarter over quarter is *TBA. Sales growth for the past five years have been 72.10% and sales growth quarter over quarter is 17.40%.

For performance, Medivation, Inc. the past week has seen a gain of 23.08%. For the last month performance for Medivation, Inc. is 27.19%. While the last quarter is 29.66% and half year, 150.53%. Finally for the year, performance is 88.78%.

The 52-week high for Medivation, Inc., is at -0.42%, and for the 52-week low it comes to a value of 204.17%. The 20-day simple moving average is 27.73% and 63.11% for the 200-day simple moving average.

Volatility for the week is at 1.62%, and for the month it is 1.69%. Medivation, Inc., has a target price of 67.

In terms of debt, long term debt/equity is 0, and for total debt/equity Medivation, Inc. has 0. The gross margin is *TBA, while operating margin is -26.30%, the profit margin is -17.20%. The current ratio is 4.3 and the quick ratio is 4.3.

Insider ownership is at 1.10%, with instituitional ownership at 91.10%. Medivation, Inc. has a payout ratio of *TBA. With the total shares outstanding coming to 166. The shares float is 163.77, with the float short at 1.78%, with short ratio coming to 0.96.

In terms of returns, the return on assets see Medivation, Inc., get -13.00%, with its returns on investment at 27.10%. Return on equity is -23.80%. So will the investors see the target price of 67, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Mark Hines

Leave a Comment